The influence of ovarian cancer induced peritoneal carcinomatosis on the pharmacokinetics of albendazole in nude mice

Anticancer Research

Volumn 30, Issue 2, 2010, Pages 423-428

  Pourgholami, Mohammad H ^a   Cai, Zhao Y ^a   Chu, Stephanie W L ^a   Galettis, Peter ^a   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Albendazole; Angiogenesis; Ovarian cancer; Peritoneal carcinomatosis; Vascular endothelial growth factor

Indexed keywords

ALBENDAZOLE; ALBENDAZOLE SULFONE; ALBENDAZOLE SULFOXIDE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG PERITONEAL FLUID LEVEL; FEMALE; MOUSE; NONHUMAN; OVARY CANCER; PERITONEAL CAVITY; PERITONEUM LAVAGE; PRIORITY JOURNAL;

ALBENDAZOLE; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 77950533596     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Permuth-Wey J and Sellers TA: Epidemiology of ovarian cancer. Methods Mol Biol 472: 413-437, 2009.
2. Guardiola E, Delroeux D, Heyd B, Combe M, Lorgis V, Demarchi, M, Stein U, Royer B, Chauffert B and Pivot X: Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer. World J Surg Oncol 7: 14, 2009.
3. Mesiano S, Ferrara N and Jaffe RB: Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153: 1249-1256, 1998.
4. Mohamed F, Marchettini P, Stuart OA and Sugarbaker PH: Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother Pharmacol 52: 405-410, 2003.
5. Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo KT, Yeo TK, Sioussat TM and Dvorak HF: Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 55: 360-368, 1995.
6. Nagy JA, Benjamin L, Zeng H, Dvorak AM and Dvorak HF: Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 11: 109-119, 2008.
7. Artini PG, Ruggiero M, Monteleone P, Carpi A, Cristello F, Cela V and Genazzani AR: Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors. Biomed Pharmacother 62: 373-377, 2008.
8. Horton J: Albendazole: a broad spectrum anthelminthic for treatment of individuals and populations. Curr Opin Infect Dis 15: 599-608, 2002.
9. Vuitton DA, Bresson-Hadni, S, Giraudoux, P, Bartholomot, B, Laplante JJ, Delabrousse E, Blagosklonov O and Mantion G: Alveolar echinococcosis: from an incurable rural disease to a controlled urban infection? Presse Med, 2009.
10. Gottschall DW, Theodorides VJ and Wang R: The metabolism of benzimidazole anthelmintics. Parasitol Today 6: 115-124, 1990.
11. Cai ZY, Galettis P, Lu Y, Morris DL and Pourgholami MH: Pharmacokinetics of albendazole in New Zealand white rabbits: oral versus intraperitoneal administration. Anticancer Res 27: 417-422, 2007.
12. Pourgholami MH, Woon L, Almajd R, Akhter J, Bowery P and Morris DL: In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett 165: 43-49, 2001.
13. Pourgholami MH, Akhter J, Wang L, Lu Y and Morris DL: Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother Pharmacol 55: 425-432, 2005.
14. Khalilzadeh A, Wangoo KT, Morris DL and Pourgholami MH: Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways. Biochem Pharmacol 74: 407-414, 2007.
15. Pourgholami MH, Yan Cai Z, Lu, Y, Wang L and Monis DL: Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res 12: 1928-1935, 2006.
16. Pourgholami MH, Cai ZY, Wang L, Badar S, Links M and Morris DL: Inhibition of cell proliferation, vascular endothelial growth factor and tumor growth by albendazole. Cancer Invest 27: 171-177, 2009.
17. Mukhopadhyay T, Sasaki J, Ramesh R and Roth JA: Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res 8: 2963-2969, 2002.
18. Sasaki J, Ramesh R, Chada S, Gomyo Y, Roth JA and Mukhopadhyay T: The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther 1: 1201-1209, 2002.
19. Yenjerla M, Cox C, Wilson L and Jordan MA: Carbendazim inhibits cancer cell proliferation by suppressing microtubule dynamics. J Pharmacol Exp Ther 328: 390-398, 2009.
20. Hardin TC, Najvar LK, Rizzo J, Fothergill AW, Rinaldi MG and Graybill JR: Discrepancy between in vitro and in vivo antifungal activity of albendazole. Medical Mycology 35: 153-158, 1997.
21. Dayan AD: Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop 86: 141-159, 2003.
22. Marriner SE and Bogan JA: Pharmacokinetics of albendazole in sheep. Am J Vet Res 41: 1126-1129, 1980.
23. Marriner SE, Morris DL, Dickson B and Bogan JA: Pharmacokinetics of albendazole in man. Eur J Clin Pharmacol 30: 705-708, 1986.
24. Rawden HC, Kokwaro GO, Ward SA and Edwards G: Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes. Br J Clin Pharmacol 49: 313-322, 2000.
25. Mohamed F, Marchettini P, Stuart OA, Yoo D and Sugarbaker PH: A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery. Eur J Surg Oncol 29: 261-265, 2003.
26. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B, Adelson MD and Hoskins WJ: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950-1955, 1996.
27. Sugarbaker PH: A curative approach to peritoneal carcinomatosis from colorectal cancer. Semin Oncol 32: S68-73, 2005.
28. Dedrick RL and Flessner MF: Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 89: 480-487, 1997.
29. Tamsma JT, Keizer HJ and Meinders AE: Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited. Ann Oncol 12: 1353-1357, 2001.
30. Jayne DG: The molecular biology of peritoneal carcinomatosis from gastrointestinal cancer. Ann Acad Med Singapore 32: 219-225, 2003.
31. Levina V, Su Y, Nolen B, Liu X, Gordin,Y, Lee M, Lokshin A and Gorelik E: Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer 123: 2031-2040, 2008.
32. Collinson FJ, Hall GD, Perren TJ and Jayson GC: Development of antiangiogenic agents for ovarian cancer. Expert Rev Anticancer Ther 8: 21-32, 2008.
33. Bates DO and Harper SJ: Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol 39: 225-237, 2002.
34. Molina AJ, Merino G, Prieto JG, Real R, Mendoza G and Alvarez AI: Absorption and metabolism of albendazole after intestinal ischemia/reperfusion. Eur J Pharm Sci 31: 16-24, 2007.
35. Morris DL, Chinnery JB and Ubhi C: A comparison of the effects of albendazole, its sulphone metabolite, and mebendazole on the viability of protoscoleces of Echinococcus granulosus in an in vitro culture system. Trans R Soc Trop Med Hyg 81: 804-806, 1987.
36. Viglietto G, Romano A, Maglione D, Rambaldi M, Paoletti I, Lago CT, Califano D, Monaco C, Mineo A, Santelli G, Manzo G, Botti G, Chiappetta G and Persico MG: Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene 13: 577-587, 1996.
37. Dvorak HF, Brown LF, Detmar M and Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039, 1995.
38. Geva E and Jaffe RB: Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril 74: 429-438, 2000.
39. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T and Jaffe RB: Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161: 1917-24, 2002.